A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the combine study)

Antiviral Therapy

Volumn 7, Issue 2, 2002, Pages 81-90

  Podzamczer, Daniel ^a   Ferrer, Elena ^a   Consiglio, Ezequiel ^a   Gatell, José Mariá ^a   Perez, Pepa ^b   Perez, José Luis ^b   Luna, Elena ^a   González, Alicia ^c   Pedrol, Enric ^d   Lozano, Luisa ^a   Ocaña, Imma ^e   Llibre, Josep María ^a   Casiró, Arnaldo ^f   Aranda, Miquel ^a   Barrufet, Pilar ^g   Martínez Lacasa, Javier ^h   Miró, José María ^a   Badía, Xavier ⁱ   Casado, Alfonso ⁱ   Lupo, Sergio ^j   Cahn, Pedro ^k   Maños, Manel ^l   Estela, Jordi ^b   Barbera M J ^b   Santin M ^b   Gudiol, F ^b   Hidalgo, M ^b   Knobel, H ^c   Sole R ^d   Azuaje, C ^e   Ribera, E ^e   Roget, M ^m   Force, Lluis ^g   Dalmau, D ^h   Suarez, C ^j   more..

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Hospital General De Agudos Teodoro Alvarez   (Argentina)

^g HOSPITAL DE MATARÓ   (Spain)

^h HOSPITAL MÚTUA DE TERRASSA   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j CAICI   (Argentina)

^k FUNDACIÓN HUÉSPED   (Argentina)

^l Ciutat Sanitaria de Bellvitge   (Spain)

^m Hospital Comarcal de Terrassa   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; LAMIVUDINE; ZIDOVUDINE;

ADULT; AGED; ANEMIA; ANXIETY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; ARGENTINA; BLOOD; CEREBROSPINAL FLUID; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED; SPAIN;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARGENTINA; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NELFINAVIR; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SPAIN; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 0036592078     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Palella F Jr, Delaney K, Moorman A, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Scott D & Holmberg MD for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338:853-860.
2. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, Van Lunzen J, Antunes F, Phillips AN & Lundgren JD for the EuroSIDA Study Group. Relations among CD4 lymphocyte count nadir, antiretroviral therapy and HIV-1 disease progression: results from the EuroSIDA study. Annals of Internal Medicine 1999; 130:570-577.
3. Ferrer E, Consiglio E, Podzamczer D, Grau I, Ramón JM, Pérez JL & Gudiol F. Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice. Scandinavian Journal of Infectious Diseases 1999; 31:495-499.
4. Carr A, Samaras K, Chisholm DJ & Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883.
5. Schechter M, Struchiner CJ & Harrison LH. Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better? AIDS 1999; 13:97-102.
6. Altice FL & Friedland GH. The era of adherence to HIV therapy. Annals of Internal Medicine 1998; 129:503-505.
7. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M & Lange JMA for the INCAS Study Group. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial: Italy, the Netherlands, Canada and Australia Study. Journal of the American Medical Association 1998; 279:930-937.
8. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamividine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 1999; 341:1865-1873.
9. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K & Pauletti D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology 1994; 68:1660-1666.
10. Bossi P, Colin D, Bricaire F & Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clinical Infectious Diseases 2000; 30:227-228.
11. Carr A & Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
12. Squires K, Johnson V, Katlama C, Murphy R, Horban A, Gatell J, Clotet B, Staszewski S, van Leeuwen R, van Eeden A, Clumeck N, Moroni M, Pavia A, Schmidt R, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Banhegyi D, Sommadossi J-P & Lange J. The Atlantic study: a randomized, open-label study to evaluate the efficacy and safety of three triple combination therapies aimed at different HIV targets in anti-retroviral naive HIV-1 infected patients. Final 48 weeks analysis. 13th International AIDS Conference. Durban, South Africa, 9-14 July 2000, Abstract LbPeB7046.
13. Schockmel GA, Yerly S & Perrin L. Detection of low HIV-1 RNA levels in plasma. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1997; 14:179-183.
14. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
15. Martínez E, Mocroft A, García-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A & Gatell JM. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-598.
16. Vernazza P, Gilliam BL, Flepp M, Dyer JR, Frank AC, Fiscus SA, Cohen MS & Eron JJ. Effect of the antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11:1249-1254.
17. Centers for Disease Control. 1993. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 1992; 41:RR-17.
18. The AVANTI Study Group. AVANTI 2: Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS 2000; 14:367-374.
19. Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R & Stevens M. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000; 14:1591-1600.
20. Eron JJ, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R & Stevens M for the START II Study Team. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals; selection of thymidine analog regimen therapy (START II). AIDS 2000; 14:1601-1610.
21. Raffi F, Reliquet V, Ferre V, Besnier JM, Zucman DZ, Raguin G, May T, Bellein V, Rozenbaum W & Milpied B. d4T + qd ddI + nevirapine (bid or qd) in antiretroviral-naive HIV-1 infected patients: 1-year results of the VIRGO study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 26-29 September 1999, Abstract 1978.
22. Pollard RB and the 1090 team. Factors predictive of durable HIV suppression in a randomized double blind trial with nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) in treatment-naive (ARV-n) patientes with advanced AIDS. 7th Conference on Retrovirus and Opportunistic Infections, San Francisco, USA, January 30-February 2 2000, Abstract 517.
23. García F, Knobel H, Sambeat MA, Arrizabalaga J, Aranda M, Romeu J, Dalmau D, Segura F, Gómez-Sirvent JL, Ferrer E, Cruceta A, Gallart T, Pumarola T, Miró JM & Gatell JM. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan study. AIDS 2000; 14:2485-2494.
24. Dybul M, Chun T-W, Ward DJ, Hertogs K, Larder B, Fox CH, Orenstein JM, Baird BF, Li Y, Green LG, Engel D, Liu S, Mican JM & Fauci AS. Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor-sparing highly active antiretroviral therapy. Journal of Infectious Diseases 2000; 181:1276-1279.
25. Ruiz L, van Lunzen J, Arno A, Stellbrink HJ, Schneider C, Rull M, Castella E, Ojanguren I, Richman DD, Clotet B, Tenner-Racz K & Racz P. Protease-inhibitor containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13:F1-F8.
26. Gisslén M, Norkrans G, Svennerholm B & Hagberg L. The effect on human immunodeficiency virus type I RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. Journal of Infectious Diseases 1997; 175:434-437.
27. Zhang H, Dornadula G, Beumont M, Livornese L, Van Vitert B, Henning K & Pomerantz RJ. Human immunodeficiency virus type-1 in the semen of men receiving highly active antiretroviral therapy. New England Journal of Medicine 1998; 339:1803-1809.
28. Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, Boggian K, Cohen MS, Fiscus SA & Eron JJ. Potent anti-retroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. AIDS 2000; 14:117-121.
29. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
30. Lewis RH & Popescu M. Lipodystrophy: results of a data evaluation of patients receiving nelfinavir-containing combination therapy. Journal of Acquired Immune Deficiency Syndromes 2000; 23:355-356.
31. Mallal SA, John M, Moore CB, James IR & McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
32. Saint-Marc T & Touraine J-L. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999; 13:2188-2189.
33. Aldeen T, Wells C, Hay P, Davidson F & Lau R. Lipodystrophy associated with nevirapine-containing anti-retroviral therapies. AIDS 1999; 13:865-867.
34. Martínez E, Conger I, Lozano L, Casamitjana R & Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13:805-810.